Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
17 août 2023 08h05 HE
|
Processa Pharmaceuticals, Inc.
Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER,...
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
10 août 2023 16h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
08 août 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focusing on developing the next...
Next Generation Chemotherapy: Improved Treatment for More Patients
14 juin 2023 16h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 14, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress
22 mai 2023 08h05 HE
|
Processa Pharmaceuticals, Inc.
Company also to provide a corporate overview in a separate session HANOVER, MD, May 22, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a...
Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
18 mai 2023 08h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug...
Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
28 avr. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis PatientsPCS12852 Improved Both Gastroparesis Symptom Scores and Gastric Emptying Rate HANOVER, MD, April ...
Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
30 mars 2023 16h01 HE
|
Processa Pharmaceuticals, Inc.
Company focused on the development of Next Generation Chemotherapy drugs in 2023 and out-licensing/business development efforts for non-oncology assets.Dose escalations continue for Next Generation...
Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
23 mars 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better...
Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
17 mars 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
The 300 mg dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given the FDA’s Project Optimus Oncology initiative.Patients...